Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.47 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27329083 | 0.85 | LMNA (0.53) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL28400448 | 0.82 | MEN1 (0.58) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL28686910 | 0.79 | SLC6A5 (0.49) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL17969447 | 0.79 | MEN1 (0.64) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL10496268 | 0.79 | MEN1 (0.64) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL17629809 | 0.78 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL1208087 | 0.78 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL4256715 | 0.78 | MEN1 (0.71) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL288777 | 0.77 | MEN1 (0.65) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL29405785 | 0.77 | MEN1 (0.65) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62134092-A | — | — | None | — | — | JP | disclosed |
| JP-62069996-A | — | — | None | — | — | JP | disclosed |
| JP-62069996-A | — | — | None | — | — | JP | disclosed |
| US-8741853-B2 | Mitochondria-targeting antioxidant therapeutics | STELIOU KOSTA (US) | 2014-06-03 | — | — | US | disclosed |
| US-20100210569-A1 | Mitochondria-targeting antioxidant therapeutics | STELIOU KOSTA | 2010-08-19 | — | — | US | disclosed |
| WO-2009038656-A1 | MITOCHONDRIA-TARGETING ANTIOXIDANT THERAPEUTICS | STELIOU KOSTA (US) | 2009-03-26 | — | — | WO | disclosed |
| CN-1255375-C | Industrial process for producing L-carnitine | SIGMA TAU IND FARMACEUTI (IT) | 2006-05-10 | — | — | CN | disclosed |
| EP-1131279-B1 | INDUSTRIAL PROCESS FOR THE PRODUCTION OF L-CARNITINE | SIGMA TAU IND FARMACEUTI (IT) | 2004-05-12 | — | — | EP | disclosed |
| US-6566552-B2 | Reduction of an alkyl 4-chloro-3 -oxobutyrate or -oxobutyr amide to 4-chloro-3 -hydroxybutyrate or -hydroxybutyramide in the presence of ruthenium complex reduction catalyst followed by quaternization with trimethylamine | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-05-20 | — | — | US | disclosed |
| US-20020165408-A1 | Industrial process for the production of L-carnitine | SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-11-07 | — | — | US | disclosed |
| CN-1326435-A | Industrial process for production of L-carnitine | SIGMA TAU IND FARMACEUTI (IT) | 2001-12-12 | — | — | CN | disclosed |
| EP-1131279-A1 | INDUSTRIAL PROCESS FOR THE PRODUCTION OF L-CARNITINE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029370-A1 | INDUSTRIAL PROCESS FOR THE PRODUCTION OF L-CARNITINE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-05-25 | — | — | WO | disclosed |
| JP-S62134092-A | PRODUCTION OF CARNITINE | BIO-LE KK | 1987-06-17 | — | — | JP | disclosed |
| JP-S6269996-A | PRODUCTION OF CARNITINE ALKYL ESTER | BIO-LE KK | 1987-03-31 | — | — | JP | disclosed |
| JP-S6269996-A | PRODUCTION OF CARNITINE ALKYL ESTER | BIO-LE KK | 1987-03-31 | — | — | JP | disclosed |
| US-4032641-A | HYPOLIPIDEMIC AGENTS | TANABE SEIYAKU CO., LTD. (JA) | 1977-06-28 | — | — | US | disclosed |
| JP-S06269996-A | — | — | 0001-01-01 | — | — | JP | disclosed |
| JP-S06269996-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165408-A1 | Industrial process for the production of L-carnitine | CRAT, CPT1B, CPT1A | MEN1 4461/4885KMT2A 240/4885CYP1A2 1461/4885 |
| US-20100210569-A1 | Mitochondria-targeting antioxidant therapeutics | SLC25A20, TXNRD2, TXN2 | MEN1 3046/4885KMT2A 4740/4885CYP1A2 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.